Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
In this phase II trial the investigators propose to evaluate ixabepilone in combination with
carboplatin and trastuzumab as neoadjuvant therapy in locally advanced breast cancer
patients. Patients with early stage, HER2-positive breast cancer will receive six cycles of
neoadjuvant treatment with ixabepilone, carboplatin, and trastuzumab every three weeks prior
to surgery; after surgery, patients will continue treatment with trastuzumab every three
weeks until week 52. Concomitant with the post-operative trastuzumab treatment, patients with
hormone receptor-positive tumors will receive anti-estrogen treatment. Also, after the
completion of chemotherapy, patients may receive radiation treatment at the discretion of
their physician.